📰 Poster Section News
Page 10 - Poster Section News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Poster Section. Real-time updates on events, politics, business and more.
March 15, 2022
/PRNewswire/ -- EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies for liquid and solid tumors,...
March 10, 2022
Oncolytics Biotech® Announces Phase 1b Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Proteasome Inhibitor Combination in Multiple Myeloma in an Abstract at the AACR Annual Meeting - read this article along with other careers information, tips and advice on BioSpace
March 10, 2022
SAN CARLOS, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel...
March 9, 2022
Preclinical data shows the robust anti-tumoral activity of BT-001, including its highly effective and safe therapeutic strategy of targeting CTLA-4STRASBOURG, France & LUND, Sweden--(BUSINESS WIRE)--Regulatory News:Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherape...
March 9, 2022
/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced phase 1b data demonstrating clinical proof-of-concept for...
March 9, 2022
At American Association for Cancer Research Annual Meeting 2022 New Orleans, April 8 13 Regulatory News: OSE Immunotherapeutics (Paris:OSE)(ISIN: FR0012127173; Mnemo: OSE), today announced that
March 9, 2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
March 9, 2022
/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced phase 1b data demonstrating clinical proof-of-concept for...
March 9, 2022
Investegate announcements from Ultimovacs ASA, Ultimovacs to Present Preclinical Data on TET Platform at American Association for Cancer Research (AACR) 2022 Annual Meeting
March 9, 2022
Oslo, March 9, 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announced that it will present data on the preclinical evaluation of the